AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36575513 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrotinib (400 mg once daily) plus trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg) and docetaxel (100 mg/m2)
Number of subjects: 355
Study 36575513 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg) and docetaxel (100 mg/m2)
Number of subjects: 355
Study 36575513 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrotinib plus trastuzumab and docetaxel
Number of subjects: 355
Study 36575513 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus trastuzumab and docetaxel
Number of subjects: 355
Study 36575531 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aid (HA) intervention group
Number of subjects: 0
Study 36575531 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study 36575536 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Pediatric Trauma Center (VPTC) model of care using telemedicine
Number of subjects: 380
Study 36575536 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (consultation with a pediatric trauma center by telephone)
Number of subjects: 380
Study 36575541 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet based on Dietary Guidelines for Americans (DGA)
Number of subjects: 44
Study 36575626 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 535
Study 36575626 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal women
Number of subjects: 535
Study 36575812 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation for 17 weeks
Number of subjects: 27
Study 36575812 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 27
Study 36575812 — intervention group
Group type: COMPARATOR
Intervention: Both groups (multidisciplinary rehabilitation and usual care)
Number of subjects: 27
Study 36575817 — intervention group
Group type: EXPERIMENTAL
Intervention: EMAeHealth intervention plus usual care
Number of subjects: 1080
Study 36575817 — intervention group
Group type: COMPARATOR
Intervention: Usual care (traditional maternal education)
Number of subjects: 1080
Study 36576026 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of MFTC MOAKS cartilage damage
Number of subjects: 599
Study 36576026 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of MFTC bone marrow lesions
Number of subjects: 599
Study 36576026 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial meniscus extrusion or damage
Number of subjects: 599
Study 36576026 — intervention group
Group type: EXPERIMENTAL
Intervention: MOAKS severity subscales for cartilage and meniscus damage
Number of subjects: 599
Study 36576026 — intervention group
Group type: EXPERIMENTAL
Intervention: Knees with presence of MRI-based pathologies
Number of subjects: 599
Study 36576026 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-based grading of articular pathologies
Number of subjects: 599
Study 36576091 — intervention group
Group type: EXPERIMENTAL
Intervention: STN1013001 (latanoprost cationic emulsion)
Number of subjects: 0
Study 36576091 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost (other formulations)
Number of subjects: 0
Study 36576173 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab plus axitinib (avelumab 10 mg/kg every 2 weeks plus axitinib 5 mg twice daily)
Number of subjects: 55
Study 36576173 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab plus axitinib
Number of subjects: 55
Study 36576188 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Assisted Guided Imagery (VRAGI)
Number of subjects: 80
Study 36576188 — intervention group
Group type: EXPERIMENTAL
Intervention: Laptop-assisted guided imagery
Number of subjects: 80
Study 36576188 — intervention group
Group type: COMPARATOR
Intervention: VR (no guided imagery)
Number of subjects: 80
Study 36576188 — intervention group
Group type: COMPARATOR
Intervention: Laptop (no guided imagery)
Number of subjects: 80
Study 36576188 — intervention group
Group type: EXPERIMENTAL
Intervention: VRAGI
Number of subjects: 80
Study 36576191 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Solving Therapy for Adherence and Depression (PST-AD) - 6 sessions
Number of subjects: 290
Study 36576191 — intervention group
Group type: COMPARATOR
Intervention: Usual care for viral non-suppression - 3 sessions of adherence counselling
Number of subjects: 290
Study 36576323 — intervention group
Group type: EXPERIMENTAL
Intervention: AVATAR protocol (cryo-balloon ablation without electrical mapping, discharged same day)
Number of subjects: 321
Study 36576323 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy (optimization of drug therapy)
Number of subjects: 321
Study 36576323 — intervention group
Group type: COMPARATOR
Intervention: Conventional ablation (cryo-balloon ablation with confirmation of pulmonary vein isolation and overnight hospitalization)
Number of subjects: 321
Study 36576342 — intervention group
Group type: EXPERIMENTAL
Intervention: Scar core mass, border zone (BZ) mass, and presence of BZ channels in patients with VA
Number of subjects: 843
Study 36576342 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of BZ channels in patients with VA
Number of subjects: 843
Study 36576342 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ≥17.2 g BZ mass and presence of BZ channels
Number of subjects: 843
Study 36576342 — intervention group
Group type: EXPERIMENTAL
Intervention: Scar characterization with CMR
Number of subjects: 843
Study 36576365 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Primary Care-Based Mindfulness Training
Number of subjects: 0
Study 36576365 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational Group
Number of subjects: 0
Study 36576430 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivozanib
Number of subjects: 172
Study 36576430 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 172
Study 36576431 — intervention group
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Number of subjects: 32
Study 36576547 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-contrast-dose group (n = 43)
Number of subjects: 90
Study 36576547 — intervention group
Group type: COMPARATOR
Intervention: Standard-contrast-dose group (n = 47)
Number of subjects: 90
Study 36576860 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal treatment for heavy menstrual bleeding
Number of subjects: 0
Study 36576875 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (Aim2Be)
Number of subjects: 0
Study 36576984 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) protocol
Number of subjects: 0
Study 36576984 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 36577040 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-3927 (an LNP encapsulating PCCA and PCCB mRNAs)
Number of subjects: 0
Study 36577040 — intervention group
Group type: COMPARATOR
Intervention: Preclinical data from mice, rats, and monkeys
Number of subjects: 0
Study 36577095 — intervention group
Group type: EXPERIMENTAL
Intervention: VV116
Number of subjects: 822
Study 36577095 — intervention group
Group type: COMPARATOR
Intervention: Nirmatrelvir-ritonavir
Number of subjects: 822
Study 36577165 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotorasib (first-in-class KRAS inhibitor)
Number of subjects: 0
Study 36577165 — intervention group
Group type: COMPARATOR
Intervention: Control arm treatment (inferior to the best standard of care)
Number of subjects: 0
Study 36577235 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training plus aerobic exercise program
Number of subjects: 39
Study 36577235 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training alone
Number of subjects: 39
Study 36577492 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive activation, site navigators, supplemental funds for milestones
Number of subjects: 19
Study 36577492 — intervention group
Group type: EXPERIMENTAL
Intervention: Site navigators
Number of subjects: 19
Study 36577492 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive site activation
Number of subjects: 19
Study 36577733 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use disorder (AUD) individuals
Number of subjects: 62
Study 36577733 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 62
Study 36577949 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastery Lifestyle Intervention (MLI)
Number of subjects: 221
Study 36577949 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Group (UCG)
Number of subjects: 221
Study 36577968 — intervention group
Group type: EXPERIMENTAL
Intervention: Malakit intervention
Number of subjects: 0
Study 36577968 — intervention group
Group type: COMPARATOR
Intervention: Control (not participants in Malakit)
Number of subjects: 0
Study 36577984 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (Roux-en-Y gastric bypass after a 7-week low energy diet); 52-week follow-up
Number of subjects: 293
Study 36577984 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention (59-week energy restricted diet and exercise program)
Number of subjects: 293
Study 36577984 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention (20-week very-low energy diet/low energy diet)
Number of subjects: 293
Study 36578002 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (SHHC-2.0): Twice-weekly experiential classes focused on exercise, nutrition, and civic engagement.
Number of subjects: 182
Study 36578002 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 182
Study 36578024 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual specialist conferences between endocrinologists and GPs (4 conferences over 12 months)
Number of subjects: 30
Study 36578024 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 30
Study 36578040 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg rivaroxaban
Number of subjects: 136
Study 36578069 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of intravenous phage (mixture of four anti-pseudomonal phages)
Number of subjects: 72
Study 36578069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 36578093 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based HIV and non-communicable disease care integrated within microfinance groups
Number of subjects: 105
Study 36578093 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment of microfinance groups
Number of subjects: 105
Study 36578093 — intervention group
Group type: EXPERIMENTAL
Intervention: Stakeholder feedback
Number of subjects: 105
Study 36578194 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg intravenously at weeks 0, 2, and 6 (induction therapy)
Number of subjects: 33
Study 36578194 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg every 8 weeks during maintenance therapy
Number of subjects: 33
Study 36578450 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy-led fall prevention intervention
Number of subjects: 0
Study 36578450 — intervention group
Group type: COMPARATOR
Intervention: Written education about fall prevention and alcohol use (control)
Number of subjects: 0
Study 36578677 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted prolonged exposure psychotherapy (PE+)
Number of subjects: 0
Study 36578806 — intervention group
Group type: EXPERIMENTAL
Intervention: Total IgG levels to Plasmodium falciparum schizont, assessed by enzyme-linked immunosorbent assay (ELISA)
Number of subjects: 252
Study 36578806 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria incidence calculated from outpatient clinic data
Number of subjects: 252
Study 36578806 — intervention group
Group type: COMPARATOR
Intervention: Comparison of incidence in high and low malaria transmission areas
Number of subjects: 252
Study 36578806 — intervention group
Group type: COMPARATOR
Intervention: Comparison of total anti-schizont antibodies by gender and study year
Number of subjects: 252
Study 36578832 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-mg ticagrelor
Number of subjects: 0
Study 36578832 — intervention group
Group type: COMPARATOR
Intervention: clopidogrel
Number of subjects: 0
Study 36578904 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT
Number of subjects: 439
Study 36578904 — intervention group
Group type: EXPERIMENTAL
Intervention: OCTA
Number of subjects: 439
Study 36578904 — intervention group
Group type: EXPERIMENTAL
Intervention: OCTA (3 × 3 mm superficial capillary plexus scan)
Number of subjects: 439
Study 36578904 — intervention group
Group type: EXPERIMENTAL
Intervention: OCTA (deep capillary plexus scan)
Number of subjects: 439
Study 36578916 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Ferrous Sulphate (FS) 200 mg three times a day for 12 weeks
Number of subjects: 54
Study 36578916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 36578945 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based training (GROUP)
Number of subjects: 54
Study 36578945 — intervention group
Group type: COMPARATOR
Intervention: Home-based training (HOME)
Number of subjects: 54
Study 36578945 — intervention group
Group type: EXPERIMENTAL
Intervention: Both GROUP and HOME
Number of subjects: 54
Study 36579179 — intervention group
Group type: EXPERIMENTAL
Intervention: Swiss low back acupuncture (SLBA) - 9-week therapy, 15 sessions total (weeks 1-6: two sessions/week, weeks 7-9: one session/week)
Number of subjects: 110
Study 36579179 — intervention group
Group type: COMPARATOR
Intervention: Standard acupuncture (SA) - 9-week therapy, 15 sessions total (weeks 1-6: two sessions/week, weeks 7-9: one session/week)
Number of subjects: 110
Study 36579349 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound 7460-0250
Number of subjects: 1
Study 36579375 — intervention group
Group type: EXPERIMENTAL
Intervention: DOAC
Number of subjects: 260
Study 36579375 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 260
Study 36579375 — intervention group
Group type: COMPARATOR
Intervention: No OAC
Number of subjects: 260
Study 36579379 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep apnea (SA)
Number of subjects: 0
Study 36579379 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery disease (CAD)
Number of subjects: 0
Study 36579379 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep apnea (SA) in patients without CAD
Number of subjects: 0
Study 36579379 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep apnea (SA) in patients with CAD
Number of subjects: 0
Study 36579406 — intervention group
Group type: EXPERIMENTAL
Intervention: VBAF detection algorithm
Number of subjects: 291
Study 36579443 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg of intramuscular nandrolone decanoate every 15 days for 2 years
Number of subjects: 17
Study 36579470 — intervention group
Group type: EXPERIMENTAL
Intervention: Body composition assessment using psoas area and density measurements
Number of subjects: 2066
Study 36579470 — intervention group
Group type: EXPERIMENTAL
Intervention: Recursive partitioning analysis (RPA) classification tree
Number of subjects: 2066
Study 36579470 — intervention group
Group type: EXPERIMENTAL
Intervention: Body composition as a factor in mortality prediction
Number of subjects: 2066
Study 36579494 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin for 3 days
Number of subjects: 4984
Study 36579494 — intervention group
Group type: COMPARATOR
Intervention: Cotrimoxazole for 5 days
Number of subjects: 4984
Study 36579617 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan low dose
Number of subjects: 0
Study 36579617 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan high dose
Number of subjects: 0
Study 36579617 — intervention group
Group type: COMPARATOR
Intervention: Ambrisentan (both doses)
Number of subjects: 0
Study 36579743 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib 180 mg once daily (days 9-28)
Number of subjects: 10
Study 36579743 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib coadministered with midazolam
Number of subjects: 10
Study 36579756 — intervention group
Group type: EXPERIMENTAL
Intervention: Subepithelial connective tissue graft (SCTG)
Number of subjects: 0
Study 36579756 — intervention group
Group type: COMPARATOR
Intervention: No connective tissue graft (NGG)
Number of subjects: 0
Study 36579859 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage I model
Number of subjects: 654
Study 36579859 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage II model
Number of subjects: 654
Study 36579859 — intervention group
Group type: EXPERIMENTAL
Intervention: External validation of Stage I model
Number of subjects: 654
Study 36579859 — intervention group
Group type: EXPERIMENTAL
Intervention: External validation of Stage II model
Number of subjects: 654
Study 36580029 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrosomial® iron (60 mg/day for one month)
Number of subjects: 594
Study 36580029 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control group)
Number of subjects: 594
Study 36580073 — intervention group
Group type: EXPERIMENTAL
Intervention: PTBi intervention package (provider mentoring using PRONTO simulation, team training, quality improvement collaboratives)
Number of subjects: 29442
Study 36580073 — intervention group
Group type: COMPARATOR
Intervention: Control group (modified WHO Safe Childbirth Checklist, data strengthening)
Number of subjects: 29442
Study 36580073 — intervention group
Group type: EXPERIMENTAL
Intervention: PTBi intervention package
Number of subjects: 29442
Study 36580304 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimodal visual-olfactory training with patient-preferred scents
Number of subjects: 275
Study 36580304 — intervention group
Group type: COMPARATOR
Intervention: Unimodal olfactory training with physician-assigned scents
Number of subjects: 275
Study 36580332 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation on postnatal day 14
Number of subjects: 874
Study 36580332 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe bronchopulmonary dysplasia (BPD) or death
Number of subjects: 874
Study 36580332 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to return to birth weight (BW)
Number of subjects: 874
Study 36580332 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak fluid balance (FB) during the first 14 postnatal days
Number of subjects: 874
Study 36580379 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly diagnosed patients with IIPs
Number of subjects: 600
Study 36580379 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive fibrosing-ILD patients
Number of subjects: 600
Study 36580441 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean arterial pressure (MAP) ≤81.5 mmHg
Number of subjects: 450
Study 36580441 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 450
Study 36580441 — intervention group
Group type: EXPERIMENTAL
Intervention: History of heart failure
Number of subjects: 450
Study 36580441 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified Pulmonary Embolism Severity Index
Number of subjects: 450
Study 36580441 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic thrombolysis
Number of subjects: 450
Study 36580441 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP ≤81.5 mmHg at admission
Number of subjects: 450
Study 36580441 — intervention group
Group type: EXPERIMENTAL
Intervention: Deteriorating group
Number of subjects: 450
Study 36580650 — intervention group
Group type: EXPERIMENTAL
Intervention: anaprazole 20 mg once daily for 4 weeks
Number of subjects: 448
Study 36580650 — intervention group
Group type: COMPARATOR
Intervention: rabeprazole 10 mg + anaprazole placebo
Number of subjects: 448
Study 36581186 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) 400 mg/100 mg twice daily for 14 days
Number of subjects: 448
Study 36581186 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Plb)
Number of subjects: 448
Study 36581413 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implant (CI) and hearing aid (HA) in a bimodal solution (CI+HA)
Number of subjects: 60
Study 36581413 — intervention group
Group type: COMPARATOR
Intervention: Bilateral hearing aids (HA+HA)
Number of subjects: 60
Study 36581426 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediabetes based on HbA1c criteria (5.7%-6.4%)
Number of subjects: 291
Study 36581426 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 291
Study 36581419 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week multimodal progressive exercise intervention delivered online
Number of subjects: 1500
Study 36581428 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised follow-up (patients attend outpatient clinic on their own initiative)
Number of subjects: 0
Study 36581428 — intervention group
Group type: COMPARATOR
Intervention: Standardised follow-up (continuing the 5-year guideline-prescribed schedule)
Number of subjects: 0
Study 36581428 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised follow-up
Number of subjects: 0
Study 36581428 — intervention group
Group type: COMPARATOR
Intervention: Standardised follow-up
Number of subjects: 0
Study 36581796 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (40 mg/kg)
Number of subjects: 777
Study 36581796 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 777
Study 36581833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Anxiety Questionnaire (CAQ)
Number of subjects: 930
Study 36581874 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative carbohydrates (CHO) supplement, 50 g carbohydrates orally the evening before surgery (20:00-24:00)
Number of subjects: 62
Study 36581874 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTRL), fasting after 20:00 the evening before surgery
Number of subjects: 62
Study 36581878 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz 50 mg
Number of subjects: 5
Study 36581878 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz 200 mg
Number of subjects: 5
Study 36581878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 36581881 — intervention group
Group type: EXPERIMENTAL
Intervention: Light Gradient Boosting Machine (LightGBM)
Number of subjects: 6891
Study 36581881 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilayer perceptron (MLP)
Number of subjects: 6891
Study 36581881 — intervention group
Group type: EXPERIMENTAL
Intervention: LightGBM
Number of subjects: 6891